Schizophrenia

Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations AIMS, abnormal involuntary movement scale; BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; BUN, blood urea nitrogen; CBC, complete blood count; CBT, cognitive behavioral therapy; CRT, cognitive remediation therapy; CT, computerized tomography; ECG, electrocardiogram; ECT, electroconvulsive therapy; EEG, electroencephalogram; EPS, extrapyramidal symptoms; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging ; NMS, neuroleptic malignant syndrome; NSA, Negative Symptoms Assessment; PANSS, Positive and Negative Symptom Scale; SNRI, serotonin norepinephrine re-uptake inhibitor; SSRI, selective serotonin re-uptake inhibitor Sources American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Washington, DC: American Psychiatric Association;2004. American Psychiatric Association. Treating schizophrenia: a quick reference guide. Washington, DC: American Psychiatric Association;2004. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. e 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71-93. Dixon L, Perkins D, Calmes C. Guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association;2009. Dixon LB, Dickerson F, Bellack AS, et al. e 2009 PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010;36(1):48-70. Kane JM, Leucht S, Carpenter D, et al. e expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. e Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010;36(1):94-103. Moore TA, Buchanan RW, Buckley PF, et al. e Texas Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-62. Scharz E, Izmailov R, Spain M, et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2012;5:39-47. Stahl SM, Morrissette DA, Citrome L, Saklad S, Cummings M, Meyer J, O'Day J, Dardashti L, Warburton K. "Meta Guidelines" for the Management of Patients with Schizophrenia [in press] Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics aer first hospitalization for schizophrenia. Am J Psychiatry. 2011 Jun;168(6):603-9. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies: info@GuidelineCentral.com Copyright © 2014 All rights reserved NEISCH14083

• Cover